EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Multisystem involvement associated with AL amyloidosis: a case report

Anton A. Karasev, Natalia G. Poteshkina, Elena A. Kovalevskaya, Elena A. Mershina, Sergei S. Usatuyk, Anna M. Svanadze

Digital Diagnostics · 2026-09-17 · 7 (3) · 411-422

DOI: 10.17816/dd707163 ↗
AbstractBibliografische Angaben

Abstract

Amyloid light-chain amyloidosis is a life-threatening systemic disorder; delayed diagnosis and treatment significantly impair patient quality of life and life expectancy. This case report presents a long-standing chronic kidney disease and arterial hypotension. Focused echocardiographic evaluation targeting the “red flags” of amyloidosis (a combination of left ventricular hypertrophy ≥ 12 mm and diastolic dysfunction) accompanied by gadolinium-enhanced cardiac magnetic resonance imaging, revealed findings characteristic of amyloid cardiomyopathy. Laboratory testing revealed abnormal production of λ light chains and ruled out multiple myeloma. Histological examination revealed multiorgan amyloid protein deposition sites in the gastrointestinal mucosa and renal parenchyma. The AL amyloidosis diagnosis was established based on these findings, enabling prompt initiation of daratumumab to suppress clonal light chain secretion and reduce amyloid protein production, which is essential for preserving duration and quality of life. This case highlights the need for comprehensive diagnostic evaluation in patients presenting with concurrent chronic kidney disease and severe myocardial hypertrophy. Integrating imaging “red flags” into routine clinical workflows alongside multimodal diagnostic algorithms enhances AL amyloidosis detection and positively impacts the disease trajectory.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →